{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:11:53Z","timestamp":1787911913971,"version":"build-2784847793"},"reference-count":211,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.bbcan.2019.05.003","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T23:20:19Z","timestamp":1559172019000},"page":"37-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma"],"prefix":"10.1016","volume":"1872","author":[{"given":"Ravindran","family":"Caspa Gokulan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica T.","family":"Garcia-Buitrago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Zaika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2019.05.003_bb0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and Mortality Rates and Trends--An Update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0015","series-title":"Global Cancer Facts & Figures","author":"Society","year":"2015"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0020","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/jnci\/djn211","article-title":"Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age","volume":"100","author":"Brown","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0025","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ng.2591","article-title":"Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity","volume":"45","author":"Dulak","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0030","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0035","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/jnci\/djg047","article-title":"Population attributable risks of esophageal and gastric cancers","volume":"95","author":"Engel","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0040","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.gastro.2015.04.053","article-title":"Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma","volume":"149","author":"Shaheen","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0045","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/j.1365-2036.2010.04471.x","article-title":"Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux","volume":"32","author":"Rubenstein","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0050","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.coph.2009.06.010","article-title":"Inflammation and esophageal carcinogenesis","volume":"9","author":"Abdel-Latif","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0055","first-page":"1161","article-title":"Prevention of DNA damage in Barrett's esophageal cells exposed to acidic bile salts","volume":"37","author":"Bhardwaj","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2036.2011.04709.x","article-title":"Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia","volume":"34","author":"McQuaid","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.gtc.2015.02.001","article-title":"Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma","volume":"44","author":"Runge","year":"2015","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0075","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0165-4608(96)00087-8","article-title":"Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia","volume":"90","author":"Menke-Pluymers","year":"1996","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0085","first-page":"6410","article-title":"11p13-15 is a specific region of chromosomal rearrangement in gastric and esophageal adenocarcinomas","volume":"50","author":"Rodriguez","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-4608(98)00036-3","article-title":"Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions","volume":"106","author":"Persons","year":"1998","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0095","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1158\/1078-0432.CCR-08-2494","article-title":"Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma","volume":"15","author":"Paulson","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/(SICI)1098-2264(199808)22:4<305::AID-GCC6>3.0.CO;2-Z","article-title":"Comparative genomic hybridization of esophageal and gastroesophageal adenocarcinomas shows consensus areas of DNA gain and loss","volume":"22","author":"Moskaluk","year":"1998","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0105","first-page":"748","article-title":"Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas","volume":"59","author":"van Dekken","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0165-4608(00)00423-4","article-title":"DNA copy number profiling in esophageal Barrett adenocarcinoma: comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma","volume":"127","author":"Varis","year":"2001","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0115","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0002-9440(10)64760-8","article-title":"Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence","volume":"156","author":"Walch","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0120","first-page":"3164","article-title":"Genomic alterations in malignant transformation of Barrett's esophagus","volume":"61","author":"Riegman","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0125","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/modpathol.3800787","article-title":"Chromosomal analysis of Barrett's cells: demonstration of instability and detection of the metaplastic lineage involved","volume":"20","author":"Chaves","year":"2007","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1572-0241.2003.07411.x","article-title":"Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma","volume":"98","author":"Suspiro","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0135","first-page":"378","article-title":"Albert Einstein College of, S. Analytical Biological, H. Barretos Cancer, M. Baylor College of, H. Beckman Research Institute of City of, et al., Integrated genomic and molecular characterization of cervical cancer","volume":"543","author":"Cancer Genome","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0140","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/ng.3357","article-title":"Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma","volume":"47","author":"Ross-Innes","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0145","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ng.3013","article-title":"Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis","volume":"46","author":"Weaver","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0150","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3659","article-title":"Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance","volume":"48","author":"Secrier","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0155","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1053\/j.gastro.2017.07.007","article-title":"The Evolving Genomic Landscape of Barrett's Esophagus and Esophageal Adenocarcinoma","volume":"153","author":"Contino","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0160","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/2159-8290.CD-12-0189","article-title":"Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma","volume":"2","author":"Agrawal","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0165","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1038\/ncomms6224","article-title":"Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis","volume":"5","author":"Nones","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13148-016-0273-7","article-title":"Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use","volume":"8","author":"Kaz","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0175","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1093\/carcin\/bgt286","article-title":"Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma","volume":"34","author":"Xu","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0180","first-page":"5021","article-title":"Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma","volume":"60","author":"Eads","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0185","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4161\/epi.6.12.18199","article-title":"DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses","volume":"6","author":"Kaz","year":"2011","journal-title":"Epigenetics"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0190","first-page":"382","article-title":"Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma","volume":"5","author":"Agarwal","year":"2012","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0195","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-12-2880","article-title":"DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus","volume":"19","author":"Alvi","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/8dcded85-a924-40f4-a7ea-56961b87447f","article-title":"Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis","volume":"7","author":"Alvarez","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2008.10.009","article-title":"Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus","volume":"275","author":"Kuester","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0210","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1038\/sj.onc.1208598","article-title":"Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk","volume":"24","author":"Schulmann","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0215","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-09-0028","article-title":"A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus","volume":"69","author":"Jin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0220","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/path.1884","article-title":"Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation","volume":"208","author":"Clement","year":"2006","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0225","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00535-009-0082-2","article-title":"Differential gene expression in normal esophagus and Barrett's esophagus","volume":"44","author":"Wang","year":"2009","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/SLA.0000000000002658","article-title":"L. Tee, J.D. James, et al., Whole Genome Methylation Analysis of Nondysplastic Barrett Esophagus that Progresses to Invasive Cancer","volume":"269","author":"Dilworth","year":"2019","journal-title":"Ann. Surg."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0235","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.18632\/oncotarget.24145","article-title":"microRNA involvement in the onset and progression of Barrett's esophagus: a systematic review","volume":"9","author":"Clark","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0240","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/cts.12242","article-title":"Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma","volume":"8","author":"Kailasam","year":"2015","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0245","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/gut.37.2.168","article-title":"Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus","volume":"37","author":"Olyaee","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0250","doi-asserted-by":"crossref","first-page":"G278","DOI":"10.1152\/ajpgi.00092.2011","article-title":"Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-kappaB activation in benign Barrett's epithelial cells","volume":"301","author":"Huo","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0255","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1158\/1078-0432.CCR-07-0483","article-title":"Activation of the interleukin-6\/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus","volume":"13","author":"Dvorak","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0260","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/carcin\/bgl147","article-title":"Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: The potential role of anti-oxidants in Barrett's oesophagus","volume":"28","author":"Jenkins","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0265","doi-asserted-by":"crossref","first-page":"9956","DOI":"10.1038\/s41598-017-09620-4","article-title":"Activation of NADPH oxidases leads to DNA damage in esophageal cells","volume":"7","author":"Bhardwaj","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0270","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/ars.2012.4886","article-title":"Methods for detection of mitochondrial and cellular reactive oxygen species","volume":"20","author":"Dikalov","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0275","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/PAI.0000000000000243","article-title":"Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma","volume":"24","author":"Almhanna","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0280","article-title":"Frequent occurrence of mitochondrial DNA mutations in Barrett's metaplasia without the presence of dysplasia","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0285","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13547500310001644961","article-title":"DNA damage levels are raised in Barrett's oesophageal mucosa relative to the squamous epithelium of the oesophagus","volume":"8","author":"Olliver","year":"2003","journal-title":"Biomarkers"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1593\/tlo.09187","article-title":"Evidence for DNA damage checkpoint activation in barrett esophagus","volume":"3","author":"von Holzen","year":"2010","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0295","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/1055-9965.EPI-04-0509","article-title":"Risk factors, DNA damage, and disease progression in Barrett's esophagus","volume":"14","author":"Olliver","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0300","doi-asserted-by":"crossref","first-page":"9083","DOI":"10.1158\/0008-5472.CAN-09-2518","article-title":"In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/carcin\/21.2.257","article-title":"Oxidative damage in an esophageal adenocarcinoma model with rats","volume":"21","author":"Chen","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0310","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.3748\/wjg.v11.i47.7436","article-title":"Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus","volume":"11","author":"Piazuelo","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0315","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1096\/fj.11-192815","article-title":"p73 protein regulates DNA damage repair","volume":"25","author":"Zaika","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0320","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.sla.0000150072.55037.e3","article-title":"The mutagenic potential of duodenoesophageal reflux","volume":"241","author":"Theisen","year":"2005","journal-title":"Ann. Surg."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7937814","article-title":"DNA Damage in CD133-Positive Cells in Barrett's Esophagus and Esophageal Adenocarcinoma","volume":"2016","author":"Thanan","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0330","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/jgh.12548","article-title":"Involvement of luminal nitric oxide in the pathogenesis of the gastroesophageal reflux disease spectrum","volume":"29","author":"Iijima","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0335","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1383-5742(99)00009-5","article-title":"Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition","volume":"443","author":"Halliwell","year":"1999","journal-title":"Mutat. Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0340","first-page":"185","article-title":"Bile acids are multifunctional modulators of the Barrett's carcinogenesis","volume":"61","author":"Burnat","year":"2010","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0345","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.athoracsur.2006.06.090","article-title":"Duodenal reflux leads to down regulation of DNA mismatch repair pathway in an animal model of esophageal cancer","volume":"83","author":"Bonde","year":"2007","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0350","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/carcin\/bgi115","article-title":"Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma","volume":"26","author":"Casson","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0355","first-page":"1077","article-title":"Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk","volume":"19","author":"Tse","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0360","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0748233709359278","article-title":"The role of oxidative DNA damage, DNA repair, GSTM1, SOD2 and OGG1 polymorphisms in individual susceptibility to Barrett's esophagus","volume":"26","author":"Kadioglu","year":"2010","journal-title":"Toxicol. Ind. Health"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0365","doi-asserted-by":"crossref","first-page":"16688","DOI":"10.18632\/oncotarget.7696","article-title":"APE1-mediated DNA damage repair provides survival advantage for esophageal adenocarcinoma cells in response to acidic bile salts","volume":"7","author":"Hong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0370","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.3748\/wjg.v11.i18.2697","article-title":"Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus","volume":"11","author":"Jimenez","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0375","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gutjnl-2013-304612","article-title":"Glutathione peroxidase 7 has potential tumour suppressor functions that are silenced by location-specific methylation in oesophageal adenocarcinoma","volume":"63","author":"Peng","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0380","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1349-7006.1999.tb00669.x","article-title":"Low glutathione and glutathione S-transferase levels in Barrett's esophagus as compared to normal esophageal epithelium","volume":"90","author":"van Lieshout","year":"1999","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0385","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/07853890701668508","article-title":"Gastroesophageal reflux patients' defective antioxidative capacity in the proximal esophageal mucosa before antireflux surgery and also after 4-year follow-up","volume":"40","author":"Rasanen","year":"2008","journal-title":"Ann. Med."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0390","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1572-0241.2008.01838.x","article-title":"Dietary antioxidants, fruits, and vegetables and the risk of Barrett's esophagus","volume":"103","author":"Kubo","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0395","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0891-5849(01)00472-5","article-title":"Oxidative damages are critical in pathogenesis of reflux esophagitis: implication of antioxidants in its treatment","volume":"30","author":"Oh","year":"2001","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0400","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/1097-0215(20000901)87:5<750::AID-IJC19>3.0.CO;2-6","article-title":"Antioxidants and cancers of the esophagus and gastric cardia","volume":"87","author":"Terry","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0405","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.gastro.2018.03.047","article-title":"Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma","volume":"155","author":"Stachler","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0410","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2559.2006.02569.x","article-title":"Barrett's oesophagus--a pathologist's view","volume":"50","author":"Flejou","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0415","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1053\/j.gastro.2011.01.031","article-title":"A. American Gastroenterological, American Gastroenterological Association technical review on the management of Barrett's esophagus","volume":"140","author":"Spechler","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0420","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2559.2009.03288.x","article-title":"Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry","volume":"54","author":"Kaye","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0425","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1136\/gutjnl-2012-303594","article-title":"Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus","volume":"62","author":"Kastelein","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0430","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/j.1572-0241.2002.06032.x","article-title":"p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression","volume":"97","author":"Skacel","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0435","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/j.1572-0241.2001.04236.x","article-title":"Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression","volume":"96","author":"Reid","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0440","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/nyas.13134","article-title":"Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma","volume":"1381","author":"Kalatskaya","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0445","doi-asserted-by":"crossref","first-page":"G45","DOI":"10.1152\/ajpgi.00583.2006","article-title":"Downregulation of p63 upon exposure to bile salts and acid in normal and cancer esophageal cells in culture","volume":"293","author":"Roman","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0450","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jcmgh.2018.10.017","article-title":"Gastroesophageal Reflux Induces Protein Adducts in the Esophagus","volume":"7","author":"Caspa Gokulan","year":"2019","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0455","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/carcin\/22.6.957","article-title":"Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation","volume":"22","author":"Qiao","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0460","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.freeradbiomed.2017.02.020","article-title":"Isolevuglandins as a gauge of lipid peroxidation in human tumors","volume":"106","author":"Yan","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0465","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fonc.2015.00288","article-title":"Targeting Oncogenic Mutant p53 for Cancer Therapy","volume":"5","author":"Parrales","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0470","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/gutjnl-2015-309770","article-title":"APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0475","article-title":"Inhibiting the system xC(-)\/glutathione axis selectively targets cancers with mutant-p53 accumulation","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0480","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V","article-title":"p73, a gene related to p53, is not mutated in esophageal carcinomas","volume":"78","author":"Nimura","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0485","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.cdd.4401897","article-title":"The role of p53 protein family in gastrointestinal malignancies","volume":"13","author":"Zaika","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0490","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00000478-200105000-00002","article-title":"Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus","volume":"25","author":"Glickman","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0495","first-page":"C171","article-title":"Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium","volume":"287","author":"Daniely","year":"2004","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064306","article-title":"Proinflammatory cytokines and bile acids upregulate DeltaNp73 protein, an inhibitor of p53 and p73 tumor suppressors","volume":"8","author":"Zaika","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0505","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/gast.2002.32370","article-title":"p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus","volume":"122","author":"Bian","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0510","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/PAI.0b013e318168598b","article-title":"p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus","volume":"16","author":"Shi","year":"2008","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0515","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.4236\/jct.2012.36143","article-title":"Immunohistochemical Expression of Ki-67, PCNA, pRb, p16, p53, Bcl-2 and Bax in Esophageal Adenocarcinoma and Barrett\u2019s Associated Dysplasia","volume":"3","author":"Andrey Iskrenov Kotzev","year":"2012","journal-title":"Journal of Cancer Therapy"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0520","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1582-4934.2008.00336.x","article-title":"Progressive silencing of p14ARF in oesophageal adenocarcinoma","volume":"13","author":"Huang","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0525","first-page":"1730","article-title":"Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma","volume":"58","author":"Singh","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0530","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/jcp.20590","article-title":"Immunohistochemical evaluation of pRb2\/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus","volume":"207","author":"Merola","year":"2006","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0535","doi-asserted-by":"crossref","first-page":"12284","DOI":"10.18632\/oncotarget.24316","article-title":"Clinical significances of p27 in digestive tract cancers: a comprehensive analysis on immunohistochemistry staining, published literatures, microarray and RNA-seq data","volume":"9","author":"Xiong","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0540","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1067\/mtc.2001.116471","article-title":"Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice","volume":"122","author":"Ellis","year":"2001","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0545","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","author":"The Cancer Genome Atlas Research","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0550","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1158\/1078-0432.CCR-11-0244","article-title":"Early G(1) cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma","volume":"17","author":"Ismail","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0555","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0046-8177(99)90227-7","article-title":"Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach","volume":"30","author":"Arber","year":"1999","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0560","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/A:1009618824145","article-title":"Roles of cyclin D1 and related genes in growth inhibition, senescence and apoptosis","volume":"4","author":"Han","year":"1999","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0565","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jnci\/92.16.1316","article-title":"Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma","volume":"92","author":"Bani-Hani","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0570","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1442-2050.1999.00034.x","article-title":"p53, p21(Waf1\/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer","volume":"12","author":"Kuwahara","year":"1999","journal-title":"Dis. Esophagus"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0575","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.seminoncol.2005.04.023","article-title":"Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis","volume":"32","author":"Izzo","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0580","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-230X-14-78","article-title":"Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies","volume":"14","author":"Zhou","year":"2014","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0585","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/gut.33.4.439","article-title":"Epidermal growth factor receptors in the oesophagus","volume":"33","author":"Jankowski","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0590","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10620-012-2316-z","article-title":"Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus","volume":"58","author":"Pretto","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0595","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/gut.33.11.1448","article-title":"Epidermal growth factor in the oesophagus","volume":"33","author":"Jankowski","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0600","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1042\/cs0810663","article-title":"Abnormal expression of growth regulatory factors in Barrett's oesophagus","volume":"81","author":"Jankowski","year":"1991","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0605","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ajg.2010.433","article-title":"Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE)","volume":"106","author":"Cronin","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0610","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/cncr.22445","article-title":"Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome","volume":"109","author":"Wang","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0615","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jcp.2005.034298","article-title":"Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study","volume":"59","author":"Langer","year":"2006","journal-title":"J. Clin. Pathol."},{"issue":"2012","key":"10.1016\/j.bbcan.2019.05.003_bb0620","article-title":"Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy","author":"Navarini","year":"2012","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0625","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s11605-013-2287-1","article-title":"Bile acid at low pH reduces squamous differentiation and activates EGFR signaling in esophageal squamous cells in 3-D culture","volume":"17","author":"Ghatak","year":"2013","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0630","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/modpathol.3800712","article-title":"Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus","volume":"20","author":"Reichelt","year":"2007","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0635","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1309\/KG1Y-XNGD-54NK-PP66","article-title":"Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions","volume":"118","author":"Geddert","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0640","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1038\/ctg.2013.2","article-title":"Insulin\/Insulin-Like Growth Factor-1 Pathway in Barrett's Carcinogenesis","volume":"4","author":"Greer","year":"2013","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0645","first-page":"3029","article-title":"The role of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in human esophageal cancer","volume":"24","author":"Sohda","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0650","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1158\/1078-0432.CCR-06-1208","article-title":"Met receptor signaling: a key effector in esophageal adenocarcinoma","volume":"12","author":"Anderson","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0655","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1593\/neo.04367","article-title":"The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma","volume":"7","author":"Herrera","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0660","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH709>3.0.CO;2-F","article-title":"Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression","volume":"192","author":"Couvelard","year":"2000","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0665","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1067\/mtc.2003.203","article-title":"Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus","volume":"125","author":"Lord","year":"2003","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0670","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1046\/j.1440-1746.2000.02163.x","article-title":"K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction","volume":"15","author":"Lord","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0675","first-page":"799","article-title":"K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus","volume":"8","author":"Trautmann","year":"1996","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0680","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/sj.onc.1207189","article-title":"Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma","volume":"23","author":"Sommerer","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0685","first-page":"880","article-title":"Differential expression of c-myc and H-ras oncogenes in Barrett's epithelium. A study using colorimetric in situ hybridization","volume":"115","author":"Abdelatif","year":"1991","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0690","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/1476-4598-9-313","article-title":"The ERK MAP kinase-PEA3\/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma","volume":"9","author":"Keld","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0695","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.humpath.2007.03.003","article-title":"Activation of the serine\/threonine protein kinase Akt during the progression of Barrett neoplasia","volume":"38","author":"Sagatys","year":"2007","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0700","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1042\/bj20031132","article-title":"Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway","volume":"377","author":"Mariette","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0705","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/cncr.25796","article-title":"Induction of MUC5AC mucin by conjugated bile acids in the esophagus involves the phosphatidylinositol 3-kinase\/protein kinase C\/activator protein-1 pathway","volume":"117","author":"Song","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0710","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/gast.2002.30993","article-title":"Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus","volume":"122","author":"Souza","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0715","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3748\/wjg.v16.i17.2080","article-title":"Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling","volume":"16","author":"Hong","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0720","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/mc.20259","article-title":"Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis","volume":"45","author":"von Rahden","year":"2006","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0725","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.1158\/0008-5472.CAN-06-1842","article-title":"In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma","volume":"66","author":"Rees","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0730","first-page":"1593","article-title":"Transforming growth factor-beta is an endogenous radioresistance factor in the esophageal adenocarcinoma cell line OE-33","volume":"23","author":"Kim","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0735","doi-asserted-by":"crossref","first-page":"189","DOI":"10.14740\/gr1009w","article-title":"Low Expression of Transforming Growth Factor beta in the Epithelium of Barrett's Esophagus","volume":"11","author":"Lee","year":"2018","journal-title":"Gastroenterology Res"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0740","doi-asserted-by":"crossref","first-page":"34228","DOI":"10.18632\/oncotarget.5349","article-title":"Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma","volume":"6","author":"Taylor","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0745","article-title":"BMP4 Signaling Is Able to Induce an Epithelial-Mesenchymal Transition-Like Phenotype in Barrett's Esophagus and Esophageal Adenocarcinoma through Induction of SNAIL2","volume":"11","author":"Kestens","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0750","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/JTO.0b013e31819c791a","article-title":"INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma","volume":"4","author":"Seder","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0755","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1378\/chest.07-1373","article-title":"Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-beta1 production and fibroblast proliferation","volume":"132","author":"Perng","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0760","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1080\/00365520902998661","article-title":"Acid and bile salt up-regulate BMP4 expression in human esophageal epithelium cells","volume":"44","author":"Zhou","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0765","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/gut.2005.076430","article-title":"Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation","volume":"55","author":"Onwuegbusi","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0770","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.25861","article-title":"Dysfunctional transforming growth factor-beta signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma","volume":"117","author":"Mendelson","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0775","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-12-1962","article-title":"Loss of TGF-beta adaptor beta2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma","volume":"73","author":"Song","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0780","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrm.2016.94","article-title":"Notch signalling in context","volume":"17","author":"Bray","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0785","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.4161\/15384101.2014.972875","article-title":"Inhibition of Notch signaling enhances transdifferentiation of the esophageal squamous epithelium towards a Barrett's-like metaplasia via KLF4","volume":"13","author":"Vega","year":"2014","journal-title":"Cell Cycle"},{"issue":"2018","key":"10.1016\/j.bbcan.2019.05.003_bb0790","article-title":"Notch Signaling Pathway Is Inhibited in the Development of Barrett's Esophagus: An In Vivo and In Vitro Study","author":"Wang","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0795","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/labinvest.2012.56","article-title":"Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus","volume":"92","author":"Tamagawa","year":"2012","journal-title":"Lab. Investig."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0800","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1158\/0008-5472.CAN-14-2051","article-title":"Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma","volume":"74","author":"Wang","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0805","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1053\/j.gastro.2007.03.026","article-title":"Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells","volume":"132","author":"Milano","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0810","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1053\/j.gastro.2010.01.048","article-title":"Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia","volume":"138","author":"Wang","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0815","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1172\/JCI66603","article-title":"Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia","volume":"124","author":"Wang","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0820","first-page":"46","article-title":"Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus","volume":"3","author":"Yang","year":"2012","journal-title":"Int J Biochem Mol Biol"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0825","doi-asserted-by":"crossref","first-page":"853","DOI":"10.18632\/oncotarget.22856","article-title":"Gli is activated and promotes epithelial-mesenchymal transition in human esophageal adenocarcinoma","volume":"9","author":"Wang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0830","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1309\/3QLC-5MF1-JYXU-A5XX","article-title":"Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus","volume":"114","author":"Bian","year":"2000","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0835","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1038\/sj.onc.1209338","article-title":"Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus","volume":"25","author":"Clement","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0840","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/path.4058","article-title":"Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus","volume":"228","author":"Moyes","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0845","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1309\/1DB6-GFVH-RA6W-Q07Y","article-title":"Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus","volume":"117","author":"Osterheld","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0850","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.neo.2015.07.006","article-title":"Wnt\/beta-Catenin Signaling Activation beyond Robust Nuclear beta-Catenin Accumulation in Nondysplastic Barrett's Esophagus: Regulation via Dickkopf-1","volume":"17","author":"Lyros","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0855","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1038\/sj.onc.1205731","article-title":"Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action","volume":"21","author":"Tselepis","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0860","first-page":"990","article-title":"Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence","volume":"96","author":"Morris","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0865","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2559.2003.01627.x","article-title":"Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma","volume":"42","author":"Lagorce","year":"2003","journal-title":"Histopathology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0870","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10620-014-3333-x","article-title":"Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking","volume":"60","author":"Nguyen","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0875","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0016-5085(00)70254-X","article-title":"Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure","volume":"118","author":"Shirvani","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0880","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1053\/gast.2001.29781","article-title":"Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids","volume":"121","author":"Zhang","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0885","first-page":"5767","article-title":"Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells","volume":"60","author":"Souza","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0890","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1053\/gast.2002.32371","article-title":"Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus","volume":"122","author":"Buttar","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0895","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.21037\/jtd.2018.03.110","article-title":"Aspirin acts in esophageal cancer: a brief review","volume":"10","author":"Hao","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0900","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1038\/bjc.2014.127","article-title":"Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis","volume":"110","author":"Zhang","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0905","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/modpathol.3800182","article-title":"Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia","volume":"17","author":"Groisman","year":"2004","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0910","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11605-007-0162-7","article-title":"Duodenal-content reflux into the esophagus leads to expression of Cdx2 and Muc2 in areas of squamous epithelium in rats","volume":"11","author":"Pera","year":"2007","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0915","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10620-005-2452-9","article-title":"Expression of Cdx2 in early GRCL of Barrett's esophagus induced in rats by duodenal reflux","volume":"50","author":"Tatsuta","year":"2005","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0920","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gut.2005.066209","article-title":"Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium","volume":"55","author":"Kazumori","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0925","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1242\/jcs.00338","article-title":"Chronic acid exposure leads to activation of the cdx2 intestinal homeobox gene in a long-term culture of mouse esophageal keratinocytes","volume":"116","author":"Marchetti","year":"2003","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0930","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/carcin\/bgl176","article-title":"Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells","volume":"28","author":"Liu","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0935","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2010.03.035","article-title":"Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus","volume":"139","author":"Huo","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bbcan.2019.05.003_bb0940","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-8-1","article-title":"Multilayered epithelium in a rat model and human Barrett's esophagus: similar expression patterns of transcription factors and differentiation markers","volume":"8","author":"Chen","year":"2008","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0945","first-page":"4819","article-title":"Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia","volume":"9","author":"Miller","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0950","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.dld.2014.09.014","article-title":"GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma","volume":"47","author":"Pavlov","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0955","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0960","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2019.05.003_bb0965","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0970","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/COC.0000000000000114","article-title":"Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma","volume":"40","author":"Li","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0975","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","article-title":"MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib","volume":"29","author":"Lennerz","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0980","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-18-1337","article-title":"A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric\/Gastroesophageal Junction\/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors","volume":"25","author":"Van Cutsem","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0985","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/jco.2015.33.3_suppl.1","article-title":"D. Virgil et.al, , Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer","volume":"33","author":"Kwak","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0990","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2015.65.5092","article-title":"CALGB 80403 (Alliance)\/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers","volume":"34","author":"Enzinger","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb0995","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/bjc.2015.440","article-title":"Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial","volume":"114","author":"Tebbutt","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb1000","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb1005","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S1470-2045(14)70024-5","article-title":"Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial","volume":"15","author":"Dutton","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb1010","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2017-0657","article-title":"Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma","volume":"23","author":"Yoon","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2019.05.003_bb1015","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","article-title":"Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial","volume":"3","author":"Suntharalingam","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bbcan.2019.05.003_bb1020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2018.01.079","volume":"93","author":"Stahl","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2019.05.003_bb1025","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdy105","article-title":"Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75\/08)","volume":"29","author":"Ruhstaller","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb1030","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/2159-8290.CD-17-1260","article-title":"Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma","volume":"8","author":"Maron","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bbcan.2019.05.003_bb1035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jco.2016.34.4_suppl.7","article-title":"Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475)","volume":"34","author":"Doi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb1040","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bbcan.2019.05.003_bb1045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/jco.2016.34.4_suppl.6","article-title":"P.S.P.A.Ott et.al,, Safety and activity of nivolumab monotherapy in advanced and metastatic (A\/M) gastric or gastroesophageal junction cancer (GC\/GEC): Results from the CheckMate-032 study","volume":"34","author":"Le","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2019.05.003_bb1050","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2019.05.003_bb1055","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X19300617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X19300617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:25:15Z","timestamp":1759638315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X19300617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":211,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0304419X19300617"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2019.05.003","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2019.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}